Technical Analysis for UNCY - Unicycive Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 1.07 | -5.13% | -0.06 |
UNCY closed down 2.59 percent on Wednesday, May 8, 2024, on 18 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | -5.13% | |
NR7 | Range Contraction | -5.13% | |
Narrow Range Bar | Range Contraction | -5.13% | |
Calm After Storm | Range Contraction | -7.59% | |
Inside Day | Range Contraction | -7.59% | |
Crossed Above 20 DMA | Bullish | -9.15% | |
Calm After Storm | Range Contraction | -9.15% | |
Outside Day | Range Expansion | -9.15% | |
Wide Bands | Range Expansion | -9.15% | |
Calm After Storm | Range Contraction | -4.29% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 3 hours ago |
2x Volume Pace | about 3 hours ago |
1.5x Volume Pace | about 3 hours ago |
Down 5% | about 3 hours ago |
Down 3% | about 3 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Kidney Disease Kidney Nephrology Organ Failure Acute Kidney Injury Hyperphosphatemia Chemical Entity
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Kidney Disease Kidney Nephrology Organ Failure Acute Kidney Injury Hyperphosphatemia Chemical Entity
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.82 |
52 Week Low | 0.47 |
Average Volume | 398,782 |
200-Day Moving Average | 0.95 |
50-Day Moving Average | 1.31 |
20-Day Moving Average | 1.12 |
10-Day Moving Average | 1.12 |
Average True Range | 0.10 |
RSI (14) | 45.95 |
ADX | 13.83 |
+DI | 23.85 |
-DI | 19.31 |
Chandelier Exit (Long, 3 ATRs) | 1.08 |
Chandelier Exit (Short, 3 ATRs) | 1.25 |
Upper Bollinger Bands | 1.26 |
Lower Bollinger Band | 0.99 |
Percent B (%b) | 0.52 |
BandWidth | 23.51 |
MACD Line | -0.04 |
MACD Signal Line | -0.06 |
MACD Histogram | 0.015 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.19 | ||||
Resistance 3 (R3) | 1.19 | 1.17 | 1.18 | ||
Resistance 2 (R2) | 1.17 | 1.15 | 1.17 | 1.18 | |
Resistance 1 (R1) | 1.15 | 1.15 | 1.14 | 1.15 | 1.17 |
Pivot Point | 1.13 | 1.13 | 1.13 | 1.13 | 1.13 |
Support 1 (S1) | 1.11 | 1.11 | 1.10 | 1.11 | 1.09 |
Support 2 (S2) | 1.09 | 1.11 | 1.09 | 1.08 | |
Support 3 (S3) | 1.07 | 1.09 | 1.08 | ||
Support 4 (S4) | 1.07 |